Clinical Trials

Sponsor: ADC Therapeutics SA

Sponsor Study ID: ADCT-402-202

Study Title: A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS 6)

NCT Number: NCT04699461

Phase: II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Non-Hodgkin's Lymphoma

Study Objectives: This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.



Study Documents    
(MUSC NetID required for document access)